Navigation Links
Isis Pharmaceuticals Announces Its Participation at the Upcoming,ACC 56th Annual Scientific Session in New Orleans and Its Live,Analyst/Investor Webcast Presentation

Lipid-Lowering Therapy (4:00 - 5:30 p.m. CT) Track: ACC.Vascular Disease, Hypertension, and Prevention Room: Auditorium B Presentation: 820-6 Time: 4:45 - 5:00 p.m. Speaker: Dr. John J.P. Kastelein Title: ISIS 301012, an Antisense Inhibitor of Apolipoprotein B, Produces Significant Additional Reduction of Low-Density Lipoprotein Cholesterol and Apolipoprotein B in Hypercholesterolemic Subjects on Statins Not Meeting Target Tuesday, March 27, 2007 Presentation: Isis Pharmaceuticals' Live Analyst/Investor Webcast Time: 7:00 a.m. CT Where: www.isispharm.com How: Live over the Internet -- select the link on Isis' home page at the address above.

If you are unable to participate during the live webcast, the presentation will be available for replay at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of ov
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... The Bill & Melinda Gates Foundation today announced that Dr. ... Health Program. Mundel, who is currently global head of development ... will start work at the foundation on December 1. ... to lead our global health program," said Bill Gates, co-chair ...
... Kan., Sept. 13, 2011 Bayer HealthCare LLC, Animal ... treatment system at its U.S. headquarters in Shawnee, Kan. ... one million gallons of water, or the equivalent of ... proprietary wastewater system began in early 2010 by CDI ...
Cached Medicine Technology:Gates Foundation Names Dr. Trevor Mundel to Lead Global Health Program 2Bayer Conserves One Million Gallons of Water through Wastewater Treatment Process at Shawnee Headquarters 2Bayer Conserves One Million Gallons of Water through Wastewater Treatment Process at Shawnee Headquarters 3Bayer Conserves One Million Gallons of Water through Wastewater Treatment Process at Shawnee Headquarters 4
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
(Date:4/22/2014)... LAKE CITY)A computational tool developed at the University of ... unknown gene mutations in three separate cases, U of ... study in The American Journal of Human Genetics ... tool), identifies undiagnosed illnesses and unknown gene mutations by ... that code for genes are made, in individual patients ...
(Date:4/22/2014)... cell lung cancer are 70 years of age or ... are not well represented in clinical trials. Therefore, the ... reach evidence based clinical recommendations. , In 2010, the ... Cancer Group along with the International Society for Geriatric ... for elderly patients with non-small cell lung cancer (NSCLC), ...
(Date:4/22/2014)... exposed to trauma, illness, alcohol or other drug abuse, ... brain cells that can go awry and activate conditions ... of autism. , Until now, it has been unclear ... a developing brain. Past studies have shown that when ... abuse or she experiences some trauma or illness, her ...
(Date:4/22/2014)... 2014) Cedars-Sinai stroke intervention researchers have been informed ... part of the National Institutes of Health, will award ... II clinical trial of an experimental drug for stroke. ... combination with recombinant tissue plasminogen activator, or rtPA ... shortly after onset. In laboratory rodent studies, 3K3A-APC, used ...
Breaking Medicine News(10 mins):Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3
... November 2, 2009 (Downey, Calif.) Aggressively managing patients at ... the United States by 25 percent, according to a Kaiser ... Journal of Bone & Joint Surgery . The first step ... osteoporosis disease management, researchers say. This study, the largest ...
... screening in high-risk study patients , MONDAY, Nov. 2 ... at high risk for lung cancer, researchers say. , ... people in Colorado who were seeing their primary care ... complete a five-minute questionnaire that collected information about lung ...
... SINGAPORE, Nov. 2 /PRNewswire-Asia/ -- GfK ... information in line with the,17th Hong Kong Optical Fair, hosted ... in October 2009 include China, Hong Kong, Korea,Singapore and Malaysia. ... be better or the same in 2010. , ...
... athletes, who wear helmets in their careers, to help erase ... YORK, Nov. 2 November is Epilepsy Awareness Month. The ... American Epilepsy Outreach Foundation (AEOF) has joined with ... Annual Helmets for Hope(TM) Campaign. The Helmets for Hope(TM) is ...
... Preliminary evaluation after completion of treatment ... has been met for patients with advanced-stage, ... 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: ... focused on endocrine therapy and oncology, today announced positive ...
... ... is expanding operations in the U.S. Martel provides custom printer solutions for products such ... equipment. Martel,s customers in the U.S. include Abbott Laboratories. , ... (PRWEB) November 2, 2009 -- Martel ...
Cached Medicine News:Health News:Nation's hip fracture rate could drop 25 percent with aggressive osteoporosis prevention 2Health News:Nation's hip fracture rate could drop 25 percent with aggressive osteoporosis prevention 3Health News:Asian Optical Retailers Upbeat about 2010 2Health News:Asian Optical Retailers Upbeat about 2010 3Health News:Helmets for Hope Campaign and Gala 2Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 2Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 3Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 4Health News:Martel Instruments Expands Its Custom Printer Solutions Business in North America; Liz Peirce Named Director of North American Business Development 2
...
...
The Lineage acetabular system with metal liners uses sophisticated manufacturing methods and materials to minimize wear debris generation....
The Pivot Bipolar was designed with a simple one-step assembly interface between the femoral head and the compression molded liner which requires no instruments and reduces OR time....
Medicine Products: